>
Yale Just Proved COVID Vaccine Injury Exists and Spike Production Persists for Years...
Time To Kash-Out the Rogue FBI
BREAKING: The Original Confirmed Creators Of COVID-19 – The Wuhan Institute – Is Now Warning...
Microsoft Majorana 1 Chip Has 8 Qubits Right Now with a Roadmap to 1 Million Raw Qubits
The car that lets you FLY over traffic jams! Futuristic £235,000 vehicle takes flight...
Floating nuclear power plants to be mass produced for US coastline
The $132 "Dumfume" LiFePO4 Battery Tested! Holy cow...
Virginia's Game-Changing Nuclear Fusion Plant Set To Deliver Clean Energy And Disrupt The Fossil
How This Woman Turned Arizona's Desert into a Farmland Oasis
3D-printed 'hydrogels' could be future space radiation shields for astronaut trips to Mars
xAI Releases Grok 3 in About 44 Hours
Flying Car vs. eVTOL: Which Is the Best New Kind of Aircraft?
NASA and General Atomics test nuclear fuel for future moon and Mars missions
In a fair fight, the immune system would wipe out cancer every time – but this crafty disease doesn't play fair. Along with its many tricks to avoid detection, tumors build microenvironments around themselves that are toxic to immune cells, draining them of energy. Sustained immune responses against a pathogen like cancer can lead to T cell exhaustion.
Finding ways to supercharge the immune system to continue the fight is the main goal of immunotherapy. Now, a team from Brigham and Women's Hospital has demonstrated a new way to refresh T cells, by essentially replacing their batteries.
Mitochondria are organelles that produce chemical energy for cells, but during T cell exhaustion these little batteries can be lost or damaged. Previous studies have shown that cancer cells can use nanotubes like "tiny tentacles" to slurp up mitochondria from immune cells. For the new study, the researchers found that they could use the same mechanism to do the opposite – donate new mitochondria to T cells, from bone marrow stromal cells (BMSCs).
The team cultured BMSCs and T cells together, and after 48 hours found that up to a quarter of the T cells had gained extra mitochondria. The researchers dubbed these juiced up immune cells Mito+.
In tests in mice, Mito+ cells were found to more easily penetrate tumors and launch a more robust attack on them. Tumors shrank drastically, and 75% of treated mice survived the full 60-day study period. In contrast, control mice saw their tumors continue to grow, and all had died by the 20-day mark.
Intriguingly, Mito+ cells could multiply quickly and pass their extra mitochondria to the new cells. Other immune cells, such as lymphocytes and CAR-Ts, also showed improved cancer-killing abilities after receiving extra mitochondria.
"These supercharged T cells overcome one of the fundamental barriers of immunotherapy by penetrating the tumor and overcoming immune barren state in the tumor," said Shiladitya Sengupta, corresponding author of the study. "Mitochondria provide the fuel. It's like we're taking T cells to the fuel station and gassing them up. This transplanting of mitochondria is the dawn of organellar therapy – where an organelle is delivered to a cell to make it more effective."